Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

NCT ID: NCT02491970

Last Updated: 2018-05-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-31
• Study Completion Date: 2017-05-31

Brief Summary

The purpose of this study is to demonstrate superiority of Fluticasone/Formoterol (Flutiform®) to Fluticasone/salmeterol based on the small airway function by assessing the Impulse Oscillometic System (IOS) in uncontrolled asthma patients requiring ICS/LABA concomitant treatment.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Fluticasone/Formoterol

Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation

Group Type: EXPERIMENTAL

Fluticasone/Formoterol

Intervention Type: DRUG

Fluticasone/Salmeterol

Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation

Group Type: ACTIVE_COMPARATOR

Fluticasone/Salmeterol

Intervention Type: DRUG

Interventions

Fluticasone/Formoterol

Intervention Type: DRUG

Fluticasone/Salmeterol

Intervention Type: DRUG

Other Intervention Names

Flutiform; Seretide

Eligibility Criteria

Inclusion Criteria

1. Adult (over 19 years) asthma patients

2. Patients who have a history of mild-to-moderate-severe, persistent asthma for at least 6 months prior to Screening.

3. Patients who were required to demonstrate a FEV1 of ≥ 40 % and ≤ 85% of predicted normal values during screening period following appropriate withholding of asthma medications (if applicable).

4. Patients who were required to show reversibility of ≥15% FEV1 after salbutamol inhalation (2 actuations, 100µg per actuation) from the pre- salbutamol value at screening

5. Patients who have uncontrolled asthma by Seretide® 250/50 defined as ACT less than 20

6. Patients who showed R5-20 more than 0.1 kPa/L/s

7. Blood eosinophil count > 300/µL on screening visit

8. Female patients of childbearing potential must have a negative urine pregnancy test at Screening.

9. Patients who are able to use the inhaler

10. Patients who is willing to voluntarily sign the study consent form

Exclusion Criteria

1. Patients who have experienced life-threatening asthma within 12 months prior to screening or respiratory infection within 4 weeks prior to screening, or patients who have experienced any emergency visit or hospitalization due to acute asthma symptoms within 4 weeks prior to screening

2. Patients who have diagnosed as clinically significant disease or non- reversible pulmonary disease or patients who currently have active pulmonary disease (eg. COPD, cystic fibrosis, bronchiectasis, active tuberculosis)

3. Patients who have diagnosed as laryngitis, chronic sinusitis, infectious rhinitis or allergic rhinitis within 4 weeks prior to screening, or patients who have had any symptoms of acute exacerbation or purulent discharge by the disease above within 2 weeks prior to screening

4. Current smoker or past smoker defined as below:

• Current smoker: smoking history within 12 months prior to screening
• Past smoker: smoking amount ≥10 pack year*

• Pack year (PY) calculation: average amount of smoking per day (pack) x duration of smoking (year)

5. Patients who currently are pregnant or lactating

6. Patient who had taken systemic corticosteroid within 4 weeks prior to screening

7. Patients who had taken omalizumab within 24 weeks prior to screening

8. Patients who had taken the following medications within 1 week prior to screening:

• potent CYP3A inhibitors
• β-blockers
• monoamine oxidase inhibitor
• TCA (tricyclic antidepressants)
• quinidine-type anti arrhythmic
• Leukotriene anatagonist
• Astemizole

9. Patients who are participating or going to participate in any interventional clinical trials

10. QT interval prolongation in ECG result at screening

11. Patients with hypersensitive to investigational products or to any component of the drug

12. Patients who are judged difficult to participate in this investigation by the investigator

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mundipharma Korea Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

FLT14-KR-401

Identifier Type: -

Identifier Source: org_study_id